Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT516 with Avelumab in Advanced Solid Tumors
NCT04551885Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ft516 in solid tumor, sponsored by Fate Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities and Severity of Dose-Limiting Toxicities at Day 29. Started Sep 2020; status: terminated.
02
Drugs
ft516
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04551885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551885.